ArticleERJ open research2020
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.
Article in ERJ open research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02414854 (A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma), which is not on this map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review.Advances in therapy · 2023Pooled it
- Pooled it
- Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma.The Cochrane database of systematic reviews · 2021Pooled it
- Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia-Pacific Region.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Trial
- Computed tomography-derived pulmonary blood volume distribution may be modifiable in asthma.ERJ open research · 2026Article
- Biomarkers of type 2 inflammation as predictors of response to biologics for severe eosinophilic asthma.ERJ open research · 2025Article
- Biologics and airway remodeling in asthma: early, late, and potential preventive effects.Allergy · 2025Review
- Increased Muc5AC and Decreased Ciliated Cells in Severe Asthma Partially Restored by Inhibition of IL-4Rα Receptor.American journal of respiratory and critical care medicine · 2024Article
- Asthma Inception: Epidemiologic Risk Factors and Natural History Across the Life Course.American journal of respiratory and critical care medicine · 2024Review
- Relief of Airflow Limitation and Airway Inflammation by Endoscopic Sinus Surgery in a Patient with Severe Asthma with Eosinophilic Chronic Rhinosinusitis.Internal medicine (Tokyo, Japan) · 2024Article
- Article
- Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity.Frontiers in pharmacology · 2023Review
- Review
- Monoclonal antibodies targeting small airways: a new perspective for biological therapies in severe asthma.Asthma research and practice · 2022Review
- Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma.Children (Basel, Switzerland) · 2022Review
- Allergic Asthma in the Era of Personalized Medicine.Journal of personalized medicine · 2022Review
- Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µLThe European respiratory journal · 2022Article
- Asthma with Fixed Airflow Obstruction: From Fixed to Personalized Approach.Journal of personalized medicine · 2022Review
- Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. In the phase 3 LIBERTY ASTHMA QUEST trial (NCT02414854) in patients with uncontrolled, moderate-to-severe asthma, add-on dupilumab 200 mg or 300 mg every 2 weeks reduced exacerbations and improved forced expiratory volume in 1 s (FEV
methodsPatients were randomised to 52 weeks of subcutaneous dupilumab 200 mg every 2 weeks, 300 mg every 2 weeks, or matched-volume placebos. Lung function outcomes were analysed in the overall population, in patients with ≥150 eosinophils·µL
resultsDupilumab treatment (200 mg and 300 mg every 2 weeks) resulted in significant improvements
conclusionsDupilumab improves lung function outcomes, including large and small airway measurements and fixed airway obstruction, in patients with uncontrolled, moderate-to-severe asthma; particularly in patients with elevated biomarkers of type 2 inflammation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.